[关于文章《与新冠肺炎死亡风险降低相关的依诺肝素剂量》的评论]
[Comment on article "Enoxaparin dose associated with decreased risk of death in COVID-19"].
作者信息
Porres-Aguilar Mateo, Anaya-Ayala Javier E
机构信息
Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, Divisions of Hospital and Adult Thrombosis Medicine, Department of Internal Medicine. El Paso, Texas, United States of America.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección de Cirugía Vascular y Terapia Endovascular, Departamento de Cirugía. Ciudad de México, México.
出版信息
Rev Med Inst Mex Seguro Soc. 2022 May 2;60(3):247-248.
Abstract
In this letter to the editor, apropos of the article "Enoxaparin dose associated with decreased risk of death in COVID-19", it is discussed the role of the current thromboprophylactic strategies, as well as the potential role of heparins in the management of COVID-19.
摘要
在这封给编辑的信中，针对《依诺肝素剂量与 COVID-19 死亡风险降低相关》这篇文章，讨论了当前血栓预防策略的作用，以及肝素在 COVID-19 治疗中的潜在作用。
相似文献
1
[Comment on article "Enoxaparin dose associated with decreased risk of death in COVID-19"].[关于文章《与新冠肺炎死亡风险降低相关的依诺肝素剂量》的评论]
Rev Med Inst Mex Seguro Soc. 2022 May 2;60(3):247-248.
2
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.随机对照试验比较高剂量与低剂量低分子肝素在需要侵入性机械通气的严重 COVID-19 肺炎和凝血病住院患者中的疗效和安全性 (COVID-19 HD)：研究方案的结构化总结。
Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.
3
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
4
Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.阿司匹林与依诺肝素预防 COVID-19 患者血栓形成和机械通气的比较：一项回顾性队列研究。
Clin Drug Investig. 2021 Aug;41(8):723-732. doi: 10.1007/s40261-021-01061-2. Epub 2021 Jul 30.
5
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.依诺肝素治疗 COVID-19 门诊患者：随机、开放标签、平行分组、多中心、III 期 OVID 试验的 90 天结果。
Thromb Res. 2023 Jan;221:157-163. doi: 10.1016/j.thromres.2022.10.021. Epub 2022 Nov 12.
6
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.COVID-19 危重症患者依诺肝素的药代动力学。
Thromb Res. 2021 Sep;205:120-127. doi: 10.1016/j.thromres.2021.07.010. Epub 2021 Jul 21.
7
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.肝素与 SARS-CoV-2：多种病理生理学关联。
Viruses. 2021 Dec 11;13(12):2486. doi: 10.3390/v13122486.
8
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病：治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验)：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
9
Enoxaparin Use in Hospitalized SARS-CoV-2-Positive Patients with Elevated D-Dimer: A Pilot Study.依诺肝素在住院的D-二聚体升高的新冠病毒阳性患者中的应用：一项初步研究。
J Pharm Pract. 2023 Jun;36(3):532-536. doi: 10.1177/08971900211064184. Epub 2021 Dec 24.
10
Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".对信件《新冠病毒肺炎患者真的需要高剂量依诺肝素进行血栓预防吗？一项新的“审慎”随机临床试验》的反驳
Blood Transfus. 2020 May;18(3):239-240. doi: 10.2450/2020.0116-20.
本文引用的文献
1
[Enoxaparin dose associated with decreased risk of death in COVID-19].[与降低COVID-19死亡风险相关的依诺肝素剂量]
Rev Med Inst Mex Seguro Soc. 2022 Feb 1;60(1):33-39.
2
Prophylactic anticoagulation in hospitalized patients with COVID-19: less is better.新冠病毒肺炎住院患者的预防性抗凝治疗：越少越好。
Gac Med Mex. 2021;157(6):640. doi: 10.24875/GMM.M21000631.
3
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
4
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
5
Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis.COVID-19 住院患者接受中等剂量或治疗剂量的血栓预防治疗的出血风险。
J Thromb Haemost. 2021 Aug;19(8):1981-1989. doi: 10.1111/jth.15400. Epub 2021 Jun 20.
6
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.COVID-19 重症监护患者中中剂量与标准剂量预防抗凝对血栓事件、体外膜肺氧合治疗或死亡率的影响：INSPIRATION 随机临床试验。
JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
Zotero 插件